Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Noveris Health SciencesMYCOF 28 EV-to-EBIT is 4.60 as of Aug. 27, 2026. GuruFocus rates MYCOF with a GF Score™ of 28/100 and a GF Value™ of $0.52 (Significantly Overvalued). Among 691 Drug Manufacturers companies, Noveris Health Sciences ranks better than 90.01% on this metric.
Noveris Health Sciences (OTCPK:MYCOF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Noveris Health Sciences's Enterprise Value for the quarter that ended in Mar. 2026 was $75.96 Mil.
Noveris Health Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Noveris Health Sciences EV-to-EBIT Related Terms
Noveris Health Sciences EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Noveris Health Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noveris Health Sciences EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Noveris Health Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Noveris Health Sciences's EV-to-EBIT falls into.
Noveris Health Sciences's current Enterprise Value is $6.03 Mil.
Noveris Health Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Noveris Health Sciences (MYCOF) has a EV-to-EBIT of 4.60 as of Aug. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Noveris Health Sciences and its competitors. According to the industry distribution chart, Noveris Health Sciences ranks #69 out of 691 companies in the Drug Manufacturers industry, placing it in the top 10%.
Is Noveris Health Sciences' EV-to-EBIT too high?
Noveris Health Sciences' current EV-to-EBIT is 4.60. The Drug Manufacturers industry median EV-to-EBIT is 15.77. Noveris Health Sciences' value of 4.60 is 70.8% below this industry median. Based on the distribution chart, Noveris Health Sciences ranks #69 out of 691 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Noveris Health Sciences has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noveris Health Sciences' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Noveris Health Sciences ranks #69 out of 691 companies for EV-to-EBIT. This places Noveris Health Sciences in the top 10% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.77. Noveris Health Sciences' value of 4.60 is 70.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.77, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Noveris Health Sciences's current EV-to-EBIT of 4.60 is 70.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Noveris Health Sciences and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noveris Health Sciences's current EV-to-EBIT is 4.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noveris Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Noveris Health Sciences (MYCOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.52, compared to a current price of $0.73 — trading 40.4% above its estimated fair value. The current EV-to-EBIT is 4.60 and 70.8% below the Drug Manufacturers industry median of 15.77. Noveris Health Sciences' overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Noveris Health Sciences (MYCOF), the current EV-to-EBIT is 4.60 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Noveris Health Sciences (MYCOF) Overvalued in 2026?
Based on GuruFocus' analysis, Noveris Health Sciences stock appears to be overvalued.
The current stock price of $0.73 is trading 40.4% above its estimated GF Value™ of $0.52.
GuruFocus considers Noveris Health Sciences to be Significantly Overvalued.
Key valuation signals for MYCOF:
EV-to-EBIT: 4.60
GF Value™: $0.52 vs. price of $0.73 (40.4% above fair value)
Industry Position: 70.8% below the Drug Manufacturers median (#69 of 691)
No single metric tells the full story. See the MYCOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Noveris Health Sciences Inc is a biotech and life sciences company dedicated to developing and commercializing solutions for treating mental health problems and enhancing vitality. The company has a portfolio of patents it is seeking to commercialize, and is exploring opportunities in the stem cell industry. It is developing the next generation of medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD).
28GF Score
Get the complete analysis for MYCOF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MYCOF has been successfully added to your 
